Renal & Urology News

FDA Approves Losartan Oral Suspension Arbli

Arbli is supplied as an peppermint-flavored oral suspension containing 10mg/mL of losartan potassium in 165mL bottles. The Food and Drug Administration (FDA) has approved Arbli ™, an oral suspension ...
Medscape

Angiotensin II-Receptor Antagonists: An Overview

Several clinical trials have demonstrated the relative tolerability of losartan. [8,14,18,19,20] The most frequent adverse reaction, as observed in a clinical trial of 2900 patients assessing the ...

SCIENTURE and BlinkRx Announce Strategic Collaboration to Expand Patient Access to Arbli™, the First FDA-Approved Ready-to-Use Oral Suspension of Losartan Potassium

U.S. Losartan market totals $245M annually with 71M prescriptions COMMACK, NY, Dec. 10, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), a holding company for existing and planned ...
Pharmabiz

Scienture and BlinkRx collaborate to expand patient access to Arbli, an oral suspension formulation of losartan potassium

Scienture and BlinkRx collaborate to expand patient access to Arbli, an oral suspension formulation of losartan potassium: Commack, New York Friday, December 12, 2025, 14:00 Hrs [ ...
Science Daily

Researchers find losartan is not effective in reducing hospitalization from mild COVID-19

In a new study, researchers determined that the common blood pressure medication, losartan, is not effective in reducing hospitalization for mildly-ill COVID-19 outpatients. University of Minnesota ...
Medscape

A Review of Olmesartan Medoxomil Monotherapy: Antihypertensive Efficacy Similar to That of Other Angiotensin II Receptor Blocker/Hydrochlorothiazide Combinations?

Abstract and Introduction Antihypertensive Efficacy of Olmesartan Medoxomil Antihypertensive Efficacy of the Leading Four ARBS Discussion References Antihypertensive Efficacy of the Leading Four ARBS ...